|
Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer |
Research Funding - Blue Earth Diagnostics (Inst) |
|
|
Speakers' Bureau - Guardant Health |
Research Funding - Bavarian Nordic (Inst); Bayer (Inst) |
|
|
Consulting or Advisory Role - Tempus |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer |
Travel, Accommodations, Expenses - Clovis Oncology (Inst); Phosplatin Therapeutics (Inst) |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen |
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst) |
|
|
Honoraria - Bayer; Dendreon; Sanofi; Seagen |
Consulting or Advisory Role - Agensys; Bayer; Dendreon |
Speakers' Bureau - Sanofi |
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst) |
Travel, Accommodations, Expenses - Agensys; Bayer; Sanofi |
Other Relationship - Caris Centers of Excellence |
|
Lakshminarayanan Nandagopal |
|
|
|
No Relationships to Disclose |
|
|
(OPTIONAL) Uncompensated Relationships - Bayer (Inst) |
|
|
Consulting or Advisory Role - Celgene; Endocyte |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Exelixis; Genomic Health; natera; Seagen |
Research Funding - Aeglea Biotherapeutics (Inst); AstraZeneca (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Compugen (Inst); Compugen (Inst); incyte (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); OBI Pharma (Inst); Peloton Therapeutics (Inst); Seagen (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst) |
Travel, Accommodations, Expenses - Caris Centers of Excellence; Genomic Health |
|
|
Honoraria - Advanced Accelerator Applications |
Travel, Accommodations, Expenses - Celgene |
|
|
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer |
|
|
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group |
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TeneoBio; Theragnostics |
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Merck (Inst); Progenics; Sanofi (Inst); SOTIO |
Expert Testimony - Sanofi |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen |
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst) |